

Received:
04 April 2018

Accepted:
04 April 2018

<https://doi.org/10.1259/bjr.20180310>

Cite this article as:

Sharma RA, Fumi L, Audisio RA, Denys A, Wood BJ, Pignatti F. Assessment of medical devices: the Emperor's new clothes: *Author reply*. *Br J Radiol* 2018; **91**: 20180310.

LETTER TO THE EDITOR

Assessment of medical devices: the Emperor's new clothes: *Author reply*

^{1,2}RICKY A SHARMA, MA, MB, BChir, FRCP, FRCR, PhD, ³LUCIO FUMI, ⁴RICCARDO A AUDISIO, ⁵ALBAN DENYS, ⁶BRADFORD J WOOD, MD and ⁷FRANCESCO PIGNATTI

¹Oncology Department, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK

²NIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, London, UK

³Wyfold Medical Consultancy, 2 Wyfold Cottages, Wyfold, Reading, Berkshire, UK

⁴Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Göteborg, Sweden

⁵Department of Radiology and Interventional Radiology, CHUV University Hospital, Lausanne, Switzerland

⁶Center for Interventional Oncology, National Cancer Institute and NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA

⁷European Medicines Agency, London, UK

Address correspondence to: Professor Ricky A Sharma

E-mail: ricky.sharma@oncology.ox.ac.uk

(The Editors do not hold themselves responsible for opinions expressed by correspondents)

To the Editor,

We thank Dr Braillon for his letter and the *British Journal of Radiology* for hosting this timely discussion.

Generating evidence for regulatory approvals is an important step in a long and complex process that aims to bring innovative devices and procedures to patients. A narrow focus on local regulatory approval may fail this aim due to the many objectives of stakeholders. Physicians and—more importantly—patients want to see proof of clinical efficacy, health-care systems want to see proof of cost-effectiveness, and companies want to see timely return on investment.

We agree that more regulatory guidance could be useful to further define and harmonise evidentiary requirements across therapeutic interventions (e.g. drugs, devices, and procedures). “Raising the bar” should, however, not neglect the need for flexible approval pathways that take into account the opportunity cost of complex evidence generation in view of the rapid pace of innovation. Indeed, we do recognise that harmonisation is challenging due to the many national and intercontinental differences (e.g. health technology assessment, legal frameworks).

In the meantime, we cannot overemphasise the role of academics and clinicians in guiding the debate on appropriate standards for approval. The science that is here to serve our patients should inform regulation, not the other way around. Health technologies and services developed to adequate scientific standards will not only meet patients' expectations, but will also help other stakeholders meet their objectives. In other words, the scientific community needs to agree on convincing yet realistic standards that will help avoiding the “valleys of death” for potentially beneficial, yet incompletely evidenced, devices and procedures.

ACKNOWLEDGEMENT

The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the organisations they are affiliated to.

FUNDING

RAS is supported by the NIHR University College London Hospitals Biomedical Research Centre and the CRUK UCL Experimental Cancer Medicines Centre.